A Phase 4 interventional study of Default dialysate sodium concentration of 137mmol/l and Default dialysate sodium concentration of 140mmol/l in End-Stage Kidney Disease, sponsored by University of Sydney. Recruiting at 264 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by University of Sydney · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Kidney Failure, Chronic with a site in United Kingdom — 15 open to participants now, 23 under way, 5 of them phase 3. Kidney Failure, Chronic · United Kingdom.
Among the 103 studies in Kidney Failure, Chronic with a site in United Kingdom, this one has the largest planned enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2016, is one of 5 in phase 4, reaches primary completion later than 7 of the 22 other live ones, and was the 54th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →15 of the 103 studies in Kidney Failure, Chronic with a site in United Kingdom are open now. Recruiting first, the newest first:
East and North Hertfordshire NHS Trust · Sites in United Kingdom
Ages 18+
East and North Hertfordshire NHS Trust · Sites in United Kingdom
Queen Mary University of London · Sites in United Kingdom
Ages 16+
CSL Behring · Sites in United Kingdom, United States, Argentina and 32 more countries
Ages 18+
W.L.Gore & Associates · Sites in United Kingdom, Germany, Italy
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 19 · Phase 4 5
First in 1994; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50,000 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 80 across the 77 interventional studies, 94 across the 26 observational. Of the 72 that completed or were terminated, 22 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 103 have an industry lead sponsor. The 10 most frequent:
University of Sydney is the lead sponsor of 94 studies on the registry; 26 are open to participants now.
University of Sydney has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
8 of the studies in Kidney Failure, Chronic with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT03994471Phase 3Iperboreal Pharma SrlEfficacy and Safety of XyloCore Peritoneal Dialysis Solution. | 2026-12-31 |
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
| NCT07713680East and North Hertfordshire NHS Trustβ2M Post-HD Rebound Prediction | 2026-11 |
| NCT02823821University of SydneyRandomised Evaluation of Sodium Dialysate Levels on Vascular Events | 2026-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 103 studies in Kidney Failure, Chronic with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.
RESOLVE is a pragmatic, cluster-randomised, open-label study designed to evaluate in real-world conditions the comparative effectiveness of two default dialysate sodium concentrations.
Dialysis sites will be randomised in a 1:1 ratio to a default dialysate sodium concentration of 137mmol/l or 140mmol/l. 'Default' is defined as the use of the allocated dialysate sodium for ≥ 90% of delivered dialysis sessions in the unit. All other care will be according to standard local practices as determined by the site.
Outcomes will be assessed on individual patients dialysing at those sites. Sites will be asked to consent to participation while waiver or opt-out consent will be sought for individual patients.
It is anticipated that site accrual will occur over 5-7 years with average study duration expected to be approximately 2-5 years. The actual length of the study will be end-point determined.
The site inclusion criteria are:
The exclusion criteria are:
Participating dialysis sites will be randomised to a default dialysate sodium concentration of 137mmol/l
Other: Default dialysate sodium concentration of 137mmol/l
Participating dialysis sites will be randomised to a default dialysate sodium concentration of 140mmol/l
Other: Default dialysate sodium concentration of 140mmol/l
Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
Time to first occurrence of an event in the primary composite outcome
Primary outcome is a composite of major cardiovascular events (hospitalised acute myocardial infarction, hospitalised stroke) and all-cause death. Study completion is endpoint driven, but is expected to be when the average follow up is around 5 years.
Time frame: Through to study completion (estimated to occur after an average of 5 years follow up)
Time to first occurrence of an event in the secondary composite outcome
Secondary outcome comprises major cardiovascular events (hospitalized acute myocardial infarction, hospitalized stroke), all-cause death and hospitalized heart failure. Study completion is endpoint driven, but is expected to be when the average follow up is around 5 years.
Time frame: Through to study completion (estimated to occur after an average of 5 years follow up)
Time to first occurrence of each of the individual components of the composite outcomes.
These components are hospitalised myocardial infarctions, hospitalised strokes, hospitalised heart failures and all-cause deaths. Study completion is endpoint driven, but is expected to be when the average follow up is around 5 years.
Time frame: Through to study completion (estimated to occur after an average of 5 years follow up)
Showing the first 100 of 264 sites across 6 countries. Choose a country and city above to see the rest.
Plan to share: No
Started Jun 2016 (actual). Primary completion is estimated for Dec 2026, 126 months after the start.
Of 52 non-industry phase 4 interventional studies under Kidney Failure, Chronic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 80. This study's planned 126 months is above that.
Counting every sponsor, half of 63 studies reached it within 31 months; a quarter within 16 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sydney